Regulatory reforms in China spark Samsung Bioepis deal with 3SBio
The regulatory reforms and growing China biopharma market has led South Korean company Samsung Bioepis Co. Ltd. (Incheon, South Korea) to expand its commercial reach via a deal with 3SBio Inc. (HKSE:1530). Samsung Bioepis said the licensing agreement with 3SBio covers several of its biosimilar candidates, including a biosimilar of cancer drug Avastin bevacizumab.
Samsung Bioepis President and CEO Christopher Ko said that the changing regulatory environment in China make it an attractive market for biosimilars. "The Chinese government reforms over the last few years have given us more confidence and clarity around what the rules will be," Ko told BioCentury. He added that, with that path forward, Samsung Bioepis identified a "credible partner with the capabilities to bring these products to the market."...